3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
18
Phase 1
15
Phase 1/2
5
Phase NA
4
Phase 3
3
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Renal Cell
5
Neuroendocrine Tumors
3
Neoplasms
3
Tuberous Sclerosis
2
Kidney Neoplasms
2
Breast Neoplasms
2
Angiomyolipoma
2
Waldenstrom Macroglobulinemia
1
Skin Neoplasms
1
Skin Diseases
1
Pancreatic Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Lymphoma
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Breast Diseases
1
Interventions
Zoledronic Acid
5
Bevacizumab
3
exemestane
2
Therapeutics
2
Standard of Care
2
Pamidronate
2
Oxaliplatin
2
Misoprostol
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ibandronic Acid
2
Fulvestrant
2
Fluorouracil
2
Cetuximab
2
Capecitabine
2
vandetanib
1
palbociclib
1
liposomal doxorubicin
1
huaier
1
eribulin
1
enzalutamide
1
darolutamide
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Vindesine
1
Trastuzumab
1
Sugars
1
Stents
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasm Metastasis
×
Everolimus
×
Clear all
NCT02248571
2017-11-13
IMPROVE
iOMEDICO AG
Phase 4
Completed
85 enrolled